Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Mack

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Midwifery Today with International Midwife|April 17, 2014
Consuming placentaRebecca Mack
Antiviral Therapy|February 7, 2009
Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirineSrinivasan Ramanathan, Thomas N Kakuda, Rebecca Mack, et al.
CNS Drugs|November 29, 2023
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy MalesMarkus Goettel, Rene Fuertig, Salome Rebecca Mack, et al.
Translational Psychiatry|August 11, 2022
Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 425809)Christian Schultheis, Holger Rosenbrock, Salome Rebecca Mack, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2008
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravirAnita A Mathias, John Hinkle, Gong Shen, et al.
Clinical Drug Investigation|December 22, 2021
The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [<sup>14</sup>C]-BI 425809 in Healthy MalesUte Burkard, Michael Desch, Yury Shatillo, et al.
Clinical Drug Investigation|March 14, 2022
Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [<sup>14</sup>C]‑BI 425809 in Healthy MalesUte Burkard, Michael Desch, Yury Shatillo, et al.
AIDS (London, England)|December 14, 2011
Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescentsChristoph Königs, Cornelia Feiterna-Sperling, Susanna Esposito, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2011
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trialsThomas N Kakuda, Samantha Abel, John Davis, et al.
AIDS (London, England)|December 31, 2008
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trialCalvin J Cohen, Daniel S Berger, Gary Blick, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Midwifery Today with International Midwife|April 17, 2014
Consuming placentaRebecca Mack
Antiviral Therapy|February 7, 2009
Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirineSrinivasan Ramanathan, Thomas N Kakuda, Rebecca Mack, et al.
CNS Drugs|November 29, 2023
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy MalesMarkus Goettel, Rene Fuertig, Salome Rebecca Mack, et al.
Translational Psychiatry|August 11, 2022
Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 425809)Christian Schultheis, Holger Rosenbrock, Salome Rebecca Mack, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2008
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravirAnita A Mathias, John Hinkle, Gong Shen, et al.
Clinical Drug Investigation|December 22, 2021
The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [<sup>14</sup>C]-BI 425809 in Healthy MalesUte Burkard, Michael Desch, Yury Shatillo, et al.
Clinical Drug Investigation|March 14, 2022
Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [<sup>14</sup>C]‑BI 425809 in Healthy MalesUte Burkard, Michael Desch, Yury Shatillo, et al.
AIDS (London, England)|December 14, 2011
Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescentsChristoph Königs, Cornelia Feiterna-Sperling, Susanna Esposito, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2011
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trialsThomas N Kakuda, Samantha Abel, John Davis, et al.
AIDS (London, England)|December 31, 2008
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trialCalvin J Cohen, Daniel S Berger, Gary Blick, et al.
Pageof 1